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Introduction
The prognosis for children with cancer diagnosed in 
Canada, the United States, and Europe is excellent, and 
most children will be cured [1]. However, treatment- related 
mortality (TRM) continues to be a major contributor to 
poor outcomes, particularly in those receiving intensive 
treatments [2, 3]. We have previously argued that under-
standing the epidemiology of TRM is fundamental to 
improving outcomes [4].
In order to address the lack of consistency in TRM 
definitions, we developed a standardized TRM definition 
and cause- of- death attribution system [4]. TRM is defined 
by the absence of progressive disease at the time of death. 
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Abstract
Using a previously developed reliable and valid treatment- related mortality (TRM) 
definition, our objective was to describe the proportion of children newly di-
agnosed with cancer experiencing TRM and to identify risk factors for TRM 
in a population- based cohort. We included children with cancer <19 years di-
agnosed and treated in Ontario who were diagnosed between 2003 and 2012. 
Children with cancer were identified using data in a provincial registry. Cumu-
lative incidence of TRM was calculated where progressive disease death was 
considered a competing event. Among the 5179 children included, 179 had 
TRM, 478 died of progressive disease, and 4522 were still alive. At 5 years, the 
cumulative incidence of TRM among the entire cohort was 3.9% (95% confi-
dence interval (CI) 3.3–4.5%). When compared to brain tumor patients, leukemia 
and lymphoma patients had a significantly higher risk of TRM (hazard ratio 
(HR) 2.5, 95% CI: 1.6–4.0; P < 0.0001). Infants were at significantly higher 
risk of TRM across diagnostic groups. Other factors associated with higher risks 
of TRM were metastatic disease (P < 0.0001), diagnosis prior to 1 January 2008 
(P = 0.001), hematopoietic stem cell transplantation (HSCT) (P < 0.0001), and 
relapse (P < 0.0001). The 5- year cumulative incidence of TRM was 3.9% among 
newly diagnosed children with cancer. Infants were at higher risk of TRM across 
diagnostic groups. Other risk factors for TRM were leukemia or lymphoma, 
metastatic disease, earlier diagnosis year, HSCT, and relapse. Future work should 
further refine prognostic factors by specific cancer diagnosis to best understand 
when and how to intervene to improve outcomes. 
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This approach was taken as many children with refrac-
tory disease will die from toxicities of therapy. The system 
is flexible as individual trials may choose to censor patients 
who relapse or those who undergo hematopoietic stem 
cell transplantation (HSCT). The developed TRM system 
was reliable and demonstrated criterion validity. We also 
found that trained clinical research associates (CRAs) 
could correctly apply the system with minimal training 
[4].
Using a population- based data source in Ontario, we 
found that TRM was responsible for 26.4% of deaths in 
pediatric cancer [5]. In this study, only patients who had 
died were included and they were divided into those who 
died from TRM versus progressive disease. Underlying 
diagnosis, younger age and absence of relapse were associ-
ated with TRM and causes of TRM differed by diagnosis 
group. However, this analysis was limited as it evaluated 
the proportion of deaths due to TRM, not the proportion 
of patients newly diagnosed with cancer who experience 
TRM. Thus, our objective was to describe the proportion 
of children newly diagnosed with cancer experiencing TRM 
and to identify risk factors for TRM in a population- based 
cohort.
Methods
Research Ethics Board approval was provided by The 
Hospital for Sick Children (SickKids), Toronto, Canada 
and the other four participating centers in Ontario. The 
requirement for informed consent was waived given the 
retrospective nature of the study.
Setting and patients
The population consisted of children newly diagnosed with 
cancer and treated in the province of Ontario, Canada. 
There are five centers in Ontario that provide care for 
pediatric cancer patients, namely London Health Sciences 
Centre (London), Hamilton Health Sciences Centre 
(Hamilton), SickKids (Toronto), Cancer Centre of 
Southeastern Ontario at Kingston (Kingston), and 
Children’s Hospital of Eastern Ontario (Ottawa). These 
centers report data to the Pediatric Oncology Group of 
Ontario Networked Information System (POGONIS), a 
population- based provincial cancer registry. POGONIS 
captures 96–98% of children 0–14 years of age diagnosed 
with cancer when compared to the Ontario Cancer Registry 
Figure 1. Flow diagram of participant identification, inclusion, and exclusion. POGONIS, Pediatric Oncology Group of Ontario Networked Information 
System.
Patients identified in POGONIS 
during study period
(N = 5659)
Excluded from analysis (N = 480)
• Duplicate (n = 421)
• Did not meet eligibility criteria (>18
years at diagnosis) (n = 57)
• Chart/data not available for TRM 
designation (n = 2)
Included in final analysis
(n = 5179)
Treatment-related 
mortality
(n = 179)
Progressive disease
(n = 478)
Still alive
(n = 4522)
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[6]. The capture rate for those 15–18 years is less com-
plete because some adolescents are diagnosed and treated 
in adult facilities.
All patients diagnosed and reported to POGONIS 
between 1 January 2003 and 31 December 2012 were 
identified. Eligible children were <19 years of age at diag-
nosis, had an underlying diagnosis of cancer, and were 
diagnosed and treated at a POGO site. We excluded 
patients that had an unconfirmed cancer diagnosis. Children 
who died and who had not been seen within 1 year prior 
to death or those whose care was provided completely 
outside a POGO center were considered inevaluable and 
excluded from the analysis unless sufficient documentation 
existed to support a TRM designation.
Treatment- related mortality designation
With the classification system, deaths are classified as TRM 
or not TRM based upon the presence of progressive dis-
ease at the time of death [4]. Deaths due to external 
causes such as accidents and suicides are considered to 
be TRM in this system. A flow diagram and educational 
material are available to facilitate training (https://www.
sungresearch.com/trm-training-manual/). Causes of death 
are assigned only for TRM and not deaths due to pro-
gressive disease. For each TRM case, probable and possible 
causes of death are assigned based upon meeting specific 
criteria; a death may have multiple probable and possible 
causes of death. A primary cause of death is not assigned 
as it is often not possible to identify a single most likely 
cause of death.
Procedure
Clinical research associates based at SickKids were trained 
in the TRM designation and cause- of- death attribution 
system [4]. They traveled to each of the five Ontario 
institutions in order to classify all deaths as TRM or not 
TRM (progressive disease). The POGONIS database pro-
vided demographic data, cancer- specific information, and 
Table 1. Demographics of the study population.
Characteristics
Total 
N = 5179
Leukemia or Lymphoma 
N = 2200
Solid Tumors 
N = 1919
Brain Tumors 
N = 1060
Demographics
Male gender 2777 (53.6%) 1258 (57.2%) 938 (48.9%) 581 (54.8%)
Median age at diagnosis 
(Range)
7.0 (0.0, 18.99) 6.9 (0.0, 18.99) 6.0 (0.0, 18.8) 7.9 (0.0–18.8)
Age group
< 1 year 493 (9.5%) 114 (5.2%) 336 (17.5%) 43 (4.1%)
1 to <5 years 1597 (30.8%) 746 (33.9%) 562 (29.3%) 289 (27.3%)
5 to <10 years 1070 (20.7%) 478 (21.7%) 269 (14.0%) 323 (30.5%)
10 to <15 years 1189 (23.0%) 485 (22.0%) 439 (22.9%) 265 (25.0%)
15 to <19 years 830 (16.0%) 377 (17.1%) 313 (16.3%) 140 (13.2%)
Metastatic disease at diagnosis 952 (18.4%) 420 (19.1%) 471 (24.5%) 61 (5.8%)
Diagnosis prior to 1 January 
2008
2435 (47.0%) 1053 (47.9%) 902 (47.0%) 480 (45.3%)
Treatments
Received surgery or 
radiotherapy
3081 (59.5%) 695 (31.6%) 1576 (82.1%) 810 (76.4%)
Received HSCT 495 (9.6%) 258 (11.7%) 150 (7.8%) 87 (8.2%)
Allogeneic 261 (5.0%) 226 (10.3%) 18 (0.9%) 17 (1.6%)
Autologous 234 (4.5%) 32 (1.5%) 132 (6.9%) 70 (6.6%)
Enrollment on clinical trial 1013 (19.6%) 676 (30.7%) 219 (11.4%) 118 (11.1%)
Outcomes
Relapse 608 (11.7%) 253 (11.5%) 240 (12.5%) 115 (10.8%)
Median months diagnosis to 
death (IQR) (n = 657)
12.7 (5.5, 23.2) 10.3 (3.4, 20.7) 14.8 (7.2, 25.8) 11.8 (5.9, 19.8)
Socioeconomic
Household income quintile
1 (Lowest) 878 (17.0%) 380 (17.3%) 321 (16.7%) 177 (16.7%)
2 927 (17.9%) 405 (18.4%) 336 (17.5%) 186 (17.5%)
3 993 (19.2%) 413 (18.8%) 370 (19.3%) 210 (19.8%)
4 1172 (22.6%) 496 (22.5%) 434 (22.6%) 242 (22.8%)
5 (Highest) 1102 (21.3%) 477 (21.7%) 409 (21.3%) 216 (20.4%)
Missing 106 (2.1%) 29 (1.3%) 48 (2.5%) 29 (2.7%)
HSCT, hematopoietic stem cell transplant; IQR, interquartile range.
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outcomes for both participants who survived and who 
died.
Statistics
We described the cumulative incidence of TRM among 
patients newly diagnosed with cancer and treated deaths 
from progressive disease as a competing event. Analyses were 
stratified by leukemia/lymphoma, solid tumor, and brain 
tumor; the risks of TRM were compared between groups 
using Gray’s test. We evaluated the following factors to 
identify if they were associated with TRM: gender, age at 
diagnosis (as a continuous variable and <1, 1 to <5, 5 to 
<10, 10 to <15 and 15 to <19 years), metastatic disease at 
diagnosis, diagnosis before 1 January 2008 (midpoint of 
study), received surgery or radiotherapy, HSCT recipient 
(overall, allogeneic and autologous), enrolled on a therapeutic 
clinical trial at initial diagnosis, relapse, and census- derived 
income quintile. Using the Statistics Canada Postal Code 
Conversion File software (PCCF+, Version 4J; Statistics 
Canada, Ottawa, Ontario, Canada), we linked the postal code 
at diagnosis to a 2001 census dissemination area. 
Dissemination areas are the smallest unit of geography defined 
by Statistics Canada; they include between 400 and 700 
persons. From the 2001 census, income quintiles were deter-
mined that adjust for household size and regional differences 
[7]. Effects were described using hazard ratios (HRs) with 
corresponding 95% confidence intervals (CIs). Statistical 
significance was defined as P value <0.05. Statistical analysis 
was conducted using the SAS statistical program (SAS- PC, 
version 9.4; SAS Institute Inc, Cary, NC).
Role of the funding source
The Pediatric Oncology Group of Ontario funded this 
study and had no role in study design, data collection, 
analysis, interpretation, writing of the report, or decision 
to submit the paper for publication.
Results
There were 5179 children newly diagnosed with cancer 
during the study period. Figure 1 illustrates the breakdown 
of patients identified, reasons for exclusion from analysis, 
and final sample size based on status. A total of 179 
children had a designation of TRM, 478 children died of 
progressive disease, and 4522 were still alive as of 31 
December 2012.
Table 1 describes the demographics of the study popu-
lation by full cohort and stratified by underlying primary 
diagnosis. The median age at diagnosis of the entire cohort 
was 7.0 years (range 0–18.99 years), and 952/5179 (18.4%) 
had metastatic disease at diagnosis. The cohort consisted 
of 2200 (42.5%) children with leukemia or lymphoma, 
1919 (37.1%) with solid tumors, and 1060 (20.5%) with 
brain tumors. Table 2 summarizes the characteristics of 
children who were alive, died of progressive disease, and 
died of TRM when stratified by underlying diagnosis.
At 5 years, the cumulative incidence of TRM among 
the entire cohort was 3.9% (95% CI: 3.3–4.5%) (Fig. 2). 
When compared to brain tumor patients, leukemia and 
lymphoma patients had a significantly higher risk of TRM 
(HR = 2.5, 95% CI: 1.6–4.0; P < 0.0001) while solid 
tumor patients did not have a different risk of TRM 
(HR = 0.9, 95% CI: 0.5–1.4; P = 0.559). Cumulative 
incidence of TRM at 5 years for patients with leukemia 
and lymphoma was 6.2%, 95% CI: 5.3–7.4%, for solid 
tumors was 2.0%, 95% CI: 1.4–2.8%, and for brain tumors 
was 2.2%, 95% CI: 1.6–3.1%.
Table 3 describes factors associated with the cumulative 
incidence of TRM overall and stratified by underlying 
diagnosis in univariate analysis. Among the entire cohort, 
older age (as a continuous variable) was significantly 
associated with a lower risk of TRM (HR = 0.97, 95% 
CI 0.94, 0.996; P = 0.027) and the effect was significant 
in those with solid tumors and brain tumors. When divided 
by age category, all age categories had a significantly lower 
risk of TRM when compared to infants <1 year of age, 
among the entire group and when stratified by diagnosis 
type. When those 15 to <19 years of age were compared 
to those 5 to <10 years, TRM was not significantly dif-
ferent among the entire group (HR = 0.89, 95% CI: 
0.54–1.47) or among leukemia or lymphoma (HR = 1.11, 
95% CI: 0.64–1.92), solid tumor (HR = 0.22, 95% CI: 
0.02–1.94), or brain tumor (HR = 0.39, 95% CI: 0.05–3.25) 
patients (data not shown). Other factors associated with 
higher risks of TRM were metastatic disease at diagnosis 
(P < 0.0001), diagnosis prior to 1 January 2008 (P = 0.001), 
absence of surgery or radiotherapy (P < 0.0001), HSCT 
Figure 2. Cumulative incidence of treatment- related mortality in the 
study cohort.
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overall (P < 0.0001), allogeneic HSCT (P < 0.0001), and 
relapse (P < 0.0001). There was no association between 
household income and TRM status.
Table 4 shows the ratio of deaths from TRM com-
pared to progressive disease where 1 means the number 
of deaths due to treatment and cancer are equivalent 
and higher numbers indicate more deaths due to TRM. 
Among the entire cohort, the TRM to progressive disease 
death ratio was 0.37. In children with leukemia and 
lymphoma, the TRM ratio in infants was 1.29. In chil-
dren with solid and brain tumors, ratios were generally 
low although the highest ratios were seen in infants 
with a ratio of 0.63 in solid tumors and a ratio of 0.71 
in brain tumors.
Discussion
In this population- based analysis of newly diagnosed chil-
dren with cancer, we found that overall, the cumulative 
incidence of TRM at 5 years was 3.9% and was highest 
among children with leukemia and lymphoma. Risk factors 
for TRM were younger age, metastatic disease, earlier diag-
nosis year, and HSCT. Household income was not associated 
with TRM. Given that children with cancer have an overall 
survival in excess of 82% [8, 9], this study suggests that 
elimination of TRM would meaningfully improve outcomes 
for the 18% of children who do not survive.
We also presented a novel approach to displaying TRM 
rates, namely the TRM to progressive disease death ratio. 
Table 4. Treatment- related mortality to progressive disease ratios.
Characteristics
Leukemia or Lymphoma 
N = 2200
Solid Tumors 
N = 1919
Brain Tumors 
N = 1060
Overall 
N = 5179
Total TRM Ratio Total TRM Ratio Total TRM Ratio Total TRM Ratio
Demographics
Gender
Male 1258 1.18 938 0.10 581 0.11 2777 0.35
Female 942 1.26 981 0.27 479 0.16 2402 0.41
Age group
<1 year 114 1.29 336 0.63 43 0.71 493 0.84
1 to <5 years 746 1.17 562 0.15 289 0.21 1597 0.35
5 to <10 years 478 1.29 269 0.11 323 0.09 1070 0.31
10 to <15 years 485 1.09 439 0.13 265 0.06 1189 0.31
15 to <19 years 377 1.28 313 0.03 140 0.05 830 0.33
Metastatic disease at diagnosis
Yes 420 0.77 471 0.14 61 0.38 952 0.28
No 1780 1.41 1448 0.20 999 0.11 4227 0.42
Diagnosis prior to January 1, 2008
Yes 1053 1.17 902 0.19 480 0.16 2435 0.39
No 1147 1.29 1017 0.14 580 0.10 2744 0.35
Treatments
Received surgery or radiotherapy
Yes 695 0.67 1576 0.13 810 0.09 3081 0.19
No 1505 1.79 343 0.34 250 0.56 2098 1.02
Received HSCT 258 1.11 150 0.12 87 0.13 495 0.50
Allogeneic 226 1.35 18 0.20 17 NA 261 1.21
Autologous 32 0.00 132 0.11 70 0.13 234 0.11
Enrollment on clinical trial
Yes 676 1.27 219 0.23 118 0.11 1013 0.46
No 1524 1.19 1700 0.16 942 0.14 4166 0.35
Outcomes
Relapse
Yes 253 0.46 240 0.03 115 0.03 608 0.17
No 1947 4.61 1679 0.34 945 0.20 4571 0.62
Socioeconomic
Household income quintile
1 (Lowest) 380 1.40 321 0.19 177 0.24 878 0.42
2 405 1.09 336 0.28 186 0.18 927 0.45
3 413 1.88 370 0.14 210 0.15 993 0.42
4 496 0.92 434 0.06 242 0.07 1172 0.25
5 (Highest) 477 1.00 409 0.27 216 0.09 1102 0.38
HSCT, hematopoietic stem cell transplant; IQR, interquartile range; PD, progressive disease; TRM, treatment- related mortality; NA, not applicable.
714 © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
P. Gibson et al.TRM in Children with Cancer
The rationale behind this ratio is that description of TRM 
alone does not place the TRM rate in context. For exam-
ple, in poor prognosis cancers, increased TRM may be 
acceptable if it achieves more cures. However, if more 
children are dying from TRM compared with progressive 
disease, supportive care should be enhanced and treatment 
intensity reduction could be considered. This data may 
also help to justify additional resources such as hospi-
talization during neutropenia. On the other hand, if the 
progressive disease death rate is higher than TRM, then 
this suggests that intensification of therapy may be appro-
priate for cancers which are sensitive to chemotherapy. 
If the rates are similar but overall survival is poor, this 
may suggest that innovative approaches are required. 
However, as with any new metric, interpretation of the 
ratio will require further application and input from 
stakeholders. Nonetheless, a ratio exceeding 1 means more 
deaths are due to TRM than progressive disease and may 
be an important benchmark.
We found that patients with leukemia or lymphoma 
were at the highest risk of TRM. This finding is not 
surprising given that several studies have identified children 
with acute lymphoblastic leukemia [2, 10], acute myeloid 
leukemia [11–13], and some non- Hodgkin’s lymphomas 
as being at higher risk of toxic mortality due to receipt 
of intensive highly myelosuppressive chemotherapy in 
addition to allogeneic HSCT [14]. The associations between 
allogeneic HSCT, metastatic disease, and relapse with more 
TRM are also not surprising and likely reflect administra-
tion of intensive therapy. We also found that receipt of 
surgery or radiotherapy was associated with a lower risk 
of TRM. This finding is likely confounded by underlying 
diagnosis since patients with solid tumors and brain tumors 
had lower TRM rates and they are the patients more 
likely to undergo surgical procedures for the removal of 
cancer and radiotherapy.
Although we found that older age was associated with 
a lower risk of TRM, the higher risk was focused on the 
infant population and not distributed across age groups. 
This finding is in contrast to several reports. Increased 
TRM was observed in adolescents 15–18 years of age with 
acute lymphoblastic leukemia when compared to younger 
children [15]. Similarly, in a study of patients with acute 
myeloid leukemia, adolescents and young adults (16 years 
of age and older) were found to be at significantly higher 
risk of TRM [16]. However, these reports included few 
or no infants and our study does not include patients 
older than 18 years of age. Both of these factors limit 
the comparability of other studies to ours.
A strength of this study is the use of consistent and 
trained CRAs to abstract the TRM data. A second strength 
is its population- based nature which improves generaliz-
ability and avoids selection bias as patients with 
comorbidities and those who present critically ill are often 
excluded from trials. However, our findings have several 
limitations. We lack detailed potential prognostic factors 
which could be important such as facility- and provider- 
related data. Second, our cohort only extends to <19 years 
of age and thus, we do not have TRM data for young 
adults, a subgroup of patients of particular importance 
given known disparities based on survival and enrollment 
on clinical trials [17]. Third, we did not include cause 
of death in this manuscript. We plan to explore cause 
of death within specific patient subgroups such that disease- 
specific characteristics can be evaluated as potential prog-
nostic factors.
In conclusion, the cumulative incidence of TRM was 
3.9% among newly diagnosed children with cancer. Infants 
were at higher risk of TRM across diagnostic groups. 
Other risk factors for TRM were leukemia or lymphoma, 
metastatic disease, earlier diagnosis year, HSCT, and relapse. 
Future work should further refine prognostic factors by 
specific cancer diagnosis to best understand when and 
how to intervene to improve outcomes.
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